2-Methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-((4-(trifluoromethyl)phenyl)methyl)benzamide
MK0767 has been used in trials studying the treatment of Dyslipidemia, Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, and Diabetes Mellitus, Type II, among others.